Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robohogs who wrote (1659)	2/13/2002 5:29:31 PM
From: Icebrg	Read Replies (1) of 10345

Jon >> Earnings going from $1.91 to $1.30 (without acquired revenue) is not growing in my book.>> Oh, but they are growing their cost base and their capital expenditure. Because they are expanding their clinical programs, increasing the sales forces and manufacturing capabilities. All things which should really be expected from a company in Elan's situation. This is not yet a grown-up pharma, but more of an aspiring biotech. To grow in the clinics and on the sales field will require that cash is spent - there is no other way. Moodys might be right in their evaluation of the company's progress seen from a bond-holders point of view. That is however to most investors in biotech shares not a very interesting view of the business. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next